^
Association details:
| Biomarker: | CLDN18.2 overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | BMS-986476 (Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors
Published date:
10/12/2022
Excerpt:
Preclinical studies were conducted to characterize TPX-4589 in CLDN18.2-positive cells....In a CLDN18.2-high patient-derived xenograft (PDX) PC tumor model, increasing doses of TPX-4589 demonstrated superior tumor growth inhibition compared to gemcitabine and LM-102, a compound with identical anti-CLDN18.2 mAb component as LM-302, and similar efficacy to LM-102 + gemcitabine in combination.
